A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer

To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects with HR-Positive/HER2-Negative solid tumor.

Trial Details

NCT ID
NCT07358377
Phase
PHASE1
Sponsor
Atridia Pty Ltd.
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • HRS-6209 Capsules and fulvestrant injection
Locations (sample)
  • Bowral, New South Wales, Australia|-34.4775,150.4204
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Elizabeth Vale, South Australia, Australia|-34.74857,138.66819
  • Ballarat, Victoria, Australia|-37.56622,143.84957

Key Eligibility Criteria

  • Ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial.
  • Adequate bone marrow and other vital organ functions
  • Adequate liver function tests
  • HR-positive or HER2-negative solid tumor patients

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →